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Key points for decision makers 41 
 Subcutaneous drug administration is used increasingly in place of intravenous drug 42 
delivery and is an alternative to oral dosing for some treatments 43 
 Studies of patients’ perspectives typically assess ease of use, patient satisfaction and 44 
fear of adverse reactions relating to treatment administration 45 
 Among the studies assessed, oral, subcutaneous infusion, intramuscular injection, and 46 
needle-free injection devices were not favoured over subcutaneous injections 47 
 48 
  49 
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Abstract 50 
 51 
Background: Subcutaneous injections allow for self-administration, but consideration of 52 
patients’ perspectives on treatment choice is important to ensure adherence. Previous 53 
systematic reviews have been limited in their scope for assessing preferences in relation to 54 
other routes of administration 55 
 56 
Aim: To examine patients’ perspectives on subcutaneously administered, self-injectable 57 
medications when compared with other routes or methods of administration for the same 58 
medicines.  59 
 60 
Methods: Nine electronic databases were searched for publications since 2000 using terms 61 
pertaining to methods of administration, choice behaviour and adverse effects. Eligibility for 62 
inclusion was determined through reference to specific criteria by two independent 63 
reviewers. Results were described narratively. 64 
 65 
Results: Of the 1,726 papers screened, 85 met the inclusion criteria. Studies were focused 66 
mainly on methods of insulin administration for diabetes but also included treatments for 67 
paediatric growth disorders, multiple sclerosis, HIV and migraine. Pen devices and 68 
autoinjectors were favoured over administration with needle and syringe; particularly with 69 
respect to ergonomics, convenience and portability.  Inhalation appeared to be more 70 
acceptable than subcutaneous injection (in the case of insulin), but it is less certain how 71 
subcutaneous infusion, intramuscular injection, and needle-free injection devices compare 72 
with subcutaneous injections in terms of patient preference.   73 
 74 
Conclusions: The review identified a number of studies showing the importance of the 75 
methods and routes of drug delivery on patient choice.  However, studies were prone to bias 76 
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and further robust evidence, based on methodologically sound approaches, is required to 77 
demonstrate how patient choice might translate to improved adherence.78 
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Introduction 79 
 80 
Patients’ attitudes towards their medicines are influenced by many factors, including their 81 
perceived (or real) benefits and harms, previous experience of use, perceptions of their 82 
illness, satisfaction with treatment and personal preferences [1]. Thus achieving optimal 83 
treatment outcomes requires that the right patients get the right choice of medicine at the 84 
right time [2]. This notion of “medicines optimisation” also encompasses encouraging 85 
patients to take their medicines correctly, avoid taking unnecessary medicines, reduce 86 
wastage of medicines, and improve medicines safety [2,3]. For some medicines, offering 87 
patients different methods or routes of drug administration may help achieve a patient-88 
centred approach to care thereby improving medication adherence, especially in the context 89 
of parenteral administration [4-6].  90 
 91 
While oral dosing is the posology of choice for chronic disease management, this may not be 92 
possible for some medicines (e.g. because of low bioavailability) or desirable for others (e.g. 93 
because of poor targeting of the site of action). The subcutaneous (SC) route of 94 
administration is being used increasingly, particularly as alternative formulations of biologics 95 
are developed for conditions such as cancers and inflammatory diseases [7]. Treatments 96 
including trastuzumab and rituximab –previously only available for intravenous 97 
administration– are now licensed for SC use. Compared with other routes of parenteral 98 
administration, subcutaneously-injectable formulations may offer advantages in terms of 99 
convenience, ease of use and the possibility of self-administration, which can also save 100 
health professionals’ time and, thus, reduce costs.  However, barriers to the use of SC 101 
injections, such as anxiety [8] and adverse, injection-site reactions [9] may have a negative 102 
impact on adherence and the benefits of such treatments. 103 
 104 
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There also exists several methods of SC administration, and patients’ satisfaction with, or 105 
preferences towards delivery devices are likely to differ. In the case of insulin, for instance, 106 
patients consider pen devices to be a more acceptable method of administration than 107 
conventional vial and syringe or pre-filled syringes [10].  These offer improved portability, 108 
convenience and ease of use and reduced injection-site pain leading to better patient 109 
satisfaction.  Compared to vials and syringes, use of insulin pen devices may consequently 110 
improve adherence and reduce healthcare resource use and associated costs [11].   111 
 112 
Whilst differences in the pharmacokinetics and efficacy of competing methods and routes of 113 
drug administration are well documented, less is known of patients’ perspectives. Relevant 114 
research methods include the use of self-reported outcomes, such as from rating and 115 
ranking scales, willingness-to-pay studies, discrete choice experiments, conjoint analyses 116 
and best-worst scaling exercise.   117 
  118 
This review aims to examine patients’ perspectives on subcutaneously administered, self-119 
injectable medications.  It focuses on study methodologies and on examining how patients’ 120 
choices compare for different devices and routes of administration. 121 
122 
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Methods 123 
 124 
The systematic review protocol was registered with the All Wales Systematic Reviews 125 
Register [12,13], conducted according to the methods of the Centre for Reviews and 126 
Dissemination [14] and reported according to the Preferred Reporting Items for Systematic 127 
Reviews and Meta-Analyses (PRISMA) statement [15].  128 
Sources searched: The following databases were searched during July 2013, using a 129 
combination of MeSH and free text searches: Embase (Ovid), CINAHL (EBSCO Host), 130 
Pubmed, Cochrane (including the Cochrane Database of Systematic Reviews), TOXLINE 131 
(ProQuest), PsycARTICLES (ProQuest), PsycINFO (ProQuest), Health & Safety Science 132 
Abstracts (ProQuest), Physical Education Index (ProQuest).  133 
Search terms: Free-text or MeSH heading terms pertaining to (i) the route of administration 134 
were combined using the Boolean operator AND with terms relevant for (ii) identifying choice 135 
behaviour and methods of elicitation, and (iii) (perceived) adverse injection-site reactions or 136 
process utility: 137 
(i) subcutaneous drug administration OR subcutaneous injections OR subcutaneous 138 
injection OR subcutaneous drug administration OR injection devices OR self injection 139 
(ii) Prefer* OR “trade-off” OR “patient participation” OR “patient satisfaction” OR “decision 140 
making” OR elicit* OR assess* OR “choice behaviour” OR “choice behavior” OR (Conjoint 141 
OR choice* AND (analys* OR experiment* OR elicit* OR assess* OR measurement) 142 
(iii) injection site pain OR injection pain OR adverse drug reaction OR injection site reaction 143 
OR cutaneous reaction OR “process utility” OR ((“treatment related attributes” OR “drug 144 
administration” OR “dose frequency”) AND (utilities OR “utility measurement”)) 145 
Inclusion criteria: Studies were included if they reported on a comparison(s) of administration 146 
of a medicinal product via SC with a different route of administration, or using a different SC 147 
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device, including hypothetical scenarios; in patients currently or likely to become responsible 148 
for self-administration of SC medication; and which measured patients’ perspectives towards 149 
to the health technology, adverse effects attributable to the method / route of administration 150 
such as pain or injection site reactions, or satisfaction. 151 
Exclusion criteria: Studies were excluded if they: were published prior to 2000; written in a 152 
language other than English; were reviews, case studies, decision models, news, 153 
correspondence, commentaries; were published as conference abstracts or posters or in 154 
books, trade journals; were animal, mechanistic or pharmacokinetic studies; assessed 155 
vaccines, anaesthesia or palliative care; or considered injection drug users or non-156 
ambulatory patients. 157 
Review methods: Titles and abstracts were read and eligibility assessment was performed 158 
independently by two reviewers.  The full manuscripts of potentially eligible studies were 159 
retrieved and assessed by both reviewers against the inclusion and exclusion criteria.  160 
Disagreements in the application of inclusion or exclusion criteria were resolved by 161 
consensus and/or consultation with two other reviewers. 162 
Outcome measures: A wide range of outcomes was considered, to reflect the various 163 
dimensions that influence patient choice: 164 
(i) Health technology-related outcomes (including ease of use, portability and convenience);  165 
(ii) Behavioural outcomes (including perceived benefits, perceived barriers, satisfaction and 166 
fear/discomfort of needles);  167 
(iii) Adverse reactions (including fear of pain and injection site reactions) 168 
 169 
Data extraction: Data were extracted on: (1) description of study; (2) characteristics of the 170 
population and intervention; (3) types of outcome measures; (4) any measured revealed 171 
preferences (adherence); (5) comparators; (6) study type; (7) results and (8) characteristics 172 
of study sponsors and links to authors. 173 
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Data analysis: Results were primarily presented narratively [14] with strength of patients’ 174 
choices assessed from the statistical significance reported or inferred from individual studies. 175 
The potential to perform a quantitative (meta)-analysis was specified a priori, conditional on 176 
a rigorous assessment of clinical, methodological and statistical heterogeneity between 177 
studies. We were cognisant of the dangers of synthesising results from diverse studies as 178 
this could lead to biased assessments and give rise to misleading results. We therefore 179 
limited any quantitative analysis of the data to studies that: (i) compared a common drug, (ii) 180 
made the same comparison among 2 (or more) devices /routes of administration (we 181 
excluded studies in which comparators were not described in full), (iii) reported a common 182 
outcome, and (iv) used a common method of assessing outcomes (methods that were not 183 
validated or not reported were excluded). Meta-analyses of eligible studies were performed 184 
in RevMan version 5 (Cochrane Collaboration) using random effects modelling to assess the 185 
pooled mean difference (for continuous variables) or odds ratio (for dichotomous variables). 186 
 187 
Results 188 
 189 
Number of studies: A total of 2,337 articles relating to patient preferences for SC 190 
medications were identified.  Following de-duplication and screening, 85 were judged 191 
suitable for inclusion.  The PRISMA flow diagram of the search and screening process is 192 
presented in Figure 1.  A summary of the main characteristics of each paper is presented in 193 
Supplementary Online Appendix 1. 194 
 195 
Study populations: Sample sizes ranged from 19 to 6,528 people. The majority involved 196 
administration of insulin for the management of diabetes (n=51 studies), followed by growth 197 
hormone deficiency (n=10), migraine (n=5) and multiple sclerosis (n=4). Other areas 198 
included HIV, infertility, contraception, chronic kidney disease, and rheumatoid arthritis. The 199 
age range of patients from whom views were obtained directly was 3.5 to 95 years. 200 
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 201 
Study characteristics:  The studies described 102 separate comparisons (Figure 2), with the 202 
majority considering alternative means of SC administration (Table 1). No details on the type 203 
of SC device were given for 16 comparisons, and there was incomplete information on how 204 
multiple daily injections (MDI) were achieved in a further 16 comparisons involving insulin.  205 
 206 
A variety of study designs were described. Forty-three were randomised studies, 29 were 207 
cross-over trials and 18 were parallel arm studies. The duration of clinical studies ranged 208 
from 1 week to 2 years. The majority used generic or disease-specific questionnaires; 16 209 
used open-ended questioning or semi-structured interviews. Nine studies used Likert scales, 210 
and 12 studies used other rating scales, including a visual analogue scale. Five studies 211 
sought to elicit stated preferences for routes of administration using choice-based methods 212 
including discrete choice experiment (DCE), adaptive conjoint analysis (ACA) and time 213 
trade-off (TTO) analysis. Some studies used simulated injections to obtain information on 214 
ease of administration. Table 2 summarises the methods used to elicit preference. 215 
 216 
The majority of studies stated links with one or more organisations likely to have commercial 217 
interest in the outcomes. The level of involvement ranged from provision of specific costs 218 
such as translation or equipment, to direct study funding and/or authorship, receipt of grants 219 
or being an advisory board member. 220 
 221 
Main study findings: Results from four studies comparing SC administration with 222 
intramuscular (IM) injection [16-19] were mixed. While one observational study of interferon-223 
beta-1a in patients with multiple sclerosis found a significant difference in patients’ desire to 224 
change or discontinue treatment adherence at 1-year in favour of IM with the number of 225 
injection site reactions reported as an important factor [16], another suggested a preference 226 
towards SC administration [17]. The findings of two studies of the contraceptive 227 
12 
 
medroxyprogesterone acetate were similarly inconclusive, with one indicating a tendency 228 
towards higher satisfaction with SC [18], and the other showing no statistically significant 229 
difference in in reported measures of satisfaction [19].  230 
  231 
Inhaled insulin was preferred to SC insulin in all included studies [20-26]. However all 232 
studies reported ties with the manufacturers of inhaled insulin technologies. The possibility of 233 
publication bias could not be rejected. 234 
 235 
Comparisons of SC injection with oral administration did not reveal any statistically 236 
significant differences in preference. In two surveys presenting hypothetical scenarios to 237 
patients with migraine, there was a tendency for the oral route being preferred, [31] and for 238 
formulation type to be more important than speed of onset [27]. However two clinical 239 
comparisons of sumatriptan suggested the opposite, with SC formulation tending to be 240 
preferred [28,29]. A DCE among patients with osteoporosis indicated that patients would be 241 
willing to pay €142 a month for a daily SC injection rather than a daily or weekly tablet [30].  242 
 243 
Four of the comparisons of oral and SC formulations in migraine also considered nasal 244 
administration but none demonstrated any statistically significant difference in preference 245 
[27-29,31].  246 
 247 
Two studies compared SC with transdermal administration [31,32]. In a crossover study of 248 
insulin delivery, significantly more patients with type 1 or 2 diabetes stated that they would 249 
switch to a patch treatment, if available [32].  250 
 251 
Among studies comparing needle-free injector devices (NFID) with SC injections, four 252 
compared enfuvirtide delivered via NFID and needle and syringe in patients with HIV. All 253 
found significant differences in favour of NFID in terms of patient-rated ease of use [33], 254 
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preference [35], or a desire to continue with the NFID at the end of the study [34, 36]. 255 
However, there was no significant difference in patient satisfaction among women self-256 
administering gonadotropin for infertility treatment [37], or in three studies of children 257 
receiving growth hormone therapy [38-40]. 258 
 259 
Nine comparisons of autoinjector devices with vial and syringe and/or pre-filled syringes 260 
(PFS) or other auto-injectors were identified. An adaptive conjoint analysis of users of growth 261 
hormone therapy revealed autoinjection to generate higher utility [38]. Autoinjectors for 262 
adalimumab were preferred to PFS and associated with less injection site pain in patients 263 
with rheumatoid arthritis [41,42]. Autoinjectors were similarly preferred for darbopoetin in 264 
chronic kidney disease [43] and for sumatriptan in migraine [48]. While one study of 265 
autoinjector devices for growth hormone found a preference among both patients and 266 
parents [45], another found less favourable scores compared with pen devices, largely due 267 
to the requirement for reconstitution [44]. Studies of interferon beta 1a autoinjectors in 268 
multiple sclerosis yielded varying results. One found no significant changes from baseline in 269 
a disease-specific treatment concern questionnaire [46] while another suggested a 270 
preference for autoinjectors [47]. 271 
 272 
Of 12 papers comparing insulin via SC catheter (mainly continuous SC infusion) with 273 
multiple daily injections (MDI) [49-60], 9 found significant differences in favour of 274 
administration by infusion, through a range of largely disease-specific measures [49-54,57-275 
59].  276 
  277 
Eighteen studies compared SC administration using pen devices with syringes, 17 using 278 
traditional syringe and vial. These were largely for insulin in diabetes, but also treatments of 279 
psoriasis [61], growth hormone deficiency [62], infertility [63,64] and hepatitis C [65]. Pens 280 
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were significantly preferred in 15 studies, particularly with respect to ease of use, 281 
convenience and portability [61-64,66-74,76-78]. 282 
 283 
The largest number of comparisons was between different pen devices, including 22 for 284 
administration of insulin [74-75,77-96], and 4 for growth hormone [97-100]. However, 13 285 
insulin and 3 growth hormone studies used simulated injections and no clinical study of pen 286 
devices was longer than 12 weeks. All claimed advantages for the novel device over 287 
comparators, with statistically significant differences in 19, but all were authored and/or 288 
sponsored by manufacturers.  289 
 290 
Among all the studies examined, only 12 assessed adherence or persistence as a revealed 291 
preference [16,19,26,35,36,40-42,62,65,71,73], and most of these relied on patient self-292 
report. 293 
 294 
Meta analyses: Four groups of studies were considered eligible for meta-analyses, each of 295 
which compared insulin delivered using pen devices versus some alternative method (see 296 
Supplementary Online Appendix 2). These were: (i) the assessment of patients’ satisfaction 297 
compared with continuous SC infusion [51,57], (ii) patient preference for a new pen device 298 
versus their existing pen device [80,81,83,92,94], (iii) preference compared with SC needle 299 
and syringe [68,71], and (iv) preferences in comparison to any existing method of 300 
administration [74,78-79]. 301 
 302 
The comparison of pen devices with SC needle and syringe yielded a pooled odds ratio of 303 
6.7 (95% confidence interval 4.6, 9.7; heterogeneity I2=0%) for patients favouring pen 304 
devices. However as this represented only 2 of 13 studies making this comparison the 305 
potential for selection bias cannot be excluded. All other comparisons we statistically 306 
heterogeneous (I2 ≥ 98%) and therefore deemed unreliable. 307 
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 308 
Discussion 309 
 310 
An understanding of patients’ perspectives on the methods and routes of drug delivery is an 311 
important consideration for maximising the effectiveness of medicines.  Our systematic 312 
review identified wide-ranging evidence using a range of methods of assessing patients’ 313 
stated and actual choice for SC versus alternative routes of drug administration, as well as 314 
between different SC injectable devices. The principal findings were: increased satisfaction 315 
and preferences with respect to the ergonomics, convenience and portability of insulin pen 316 
devices and autoinjectors as compared to needle & syringe, and more satisfaction with 317 
inhaled insulin; but no clear favouring of oral, SC infusion, intramuscular injection, and 318 
needle-free injection devices when compared with SC injections. 319 
 320 
A significant number of studies meeting our inclusion criteria were of methods of insulin 321 
delivery, reflecting developments in pen devices and the (now discontinued) inhaler, 322 
Exubera. Satisfaction with, and preference for different insulin devices and routes of 323 
administration may relate more to the necessity for a convenient and pain-free method, 324 
given the need for punctual and life-long therapy. By contrast, studies in migraine, where the 325 
need for medication is intermittent and unpredictable, having available options of routes of 326 
administration for use in different circumstances may be more important to patients than any 327 
single preferred option. These contrasts suggest that factors important for patient choice of a 328 
given route of administration will vary with the clinical situation and context of use. 329 
 330 
The number of studies comparing SC administration with oral, nasal, transdermal and 331 
intramuscular administration were each very small, and covered different therapeutic areas. 332 
None of the studies compared SC self-administration with intravenous administration by 333 
health care professionals in a clinical setting, which we perceive to be increasing with the 334 
16 
 
introduction of novel biologic therapies. The comparison with clinic-administration by IM 335 
injection of medroxyprogesterone acetate as a contraceptive was perhaps the closest 336 
situation, but neither study revealed any difference from a patient’s perspective [18,19]. 337 
Whilst our review complied with best methodological practice, the strength of our findings is 338 
limited by the weaknesses of the research identified and the variety of approaches 339 
employed. The number of studies comparing SC injection with non-SC routes was small for 340 
each route and many studies were observational, unmasked, had small sample sizes and 341 
short follow-up periods. There was general inadequacy in the descriptions of the 342 
technologies being assessed, or of the methods of analysis. Although some studies did not 343 
disclose a source of funding, the majority were supported by (or linked to) pharmaceutical 344 
companies seeking to differentiate their products from those of competitors. As more 345 
biopharmaceutical products are developed, and treatments previously administered 346 
intravenously are formulated for SC administration, more patient-centred evaluations are 347 
likely to emerge, however this should not be at the expense of methodological rigour.  348 
Reviewed studies employed a range of methods, including direct questioning of patients, 349 
typically with responses on Likert scales, for their satisfaction with or preference to different 350 
treatment options. Such surveys employed a variety of questionnaire designs, only some of 351 
which were recognised as validated. The discrete choice experiments or conjoint analyses 352 
employed in a small number of studies are a more appropriate choice-based method of 353 
preference elicitation grounded in theory [101]. There was considerable heterogeneity 354 
among studies, in terms of populations, treatments, methods of drug administration, 355 
outcome measure and measurement, to enable unbiased pooled estimates to be determined 356 
through meta-analyses in all but one comparison [102].  Combining heterogeneous studies 357 
could compromise the systematic and scientifically rigorous representation of empirical 358 
evidence that could be more accurately reported in our narrative synthesis [14]. 359 
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Our systematic review has extended previous reviews [10,103], which were restricted to 360 
comparisons of pen versus needle and syringe insulin for diabetes. Our findings suggest that 361 
differences in patients’ perspectives between methods and routes of drug delivery will affect 362 
choice of delivery device across a whole spectrum of diseases. But while evidence of patient 363 
preference – in addition to all features/attributes of medicines (such as efficacy, safety, route 364 
of administration) – may potentially add value to treatments, health technology assessments 365 
require evidence on how this improves health outcomes and /or cost-effectiveness to justify 366 
any increases in pricing. These were outside the scope of the present review, but even so, 367 
very few studies considered patient adherence to treatment that might mediate 368 
improvements in health outcomes.   369 
The implications of our findings are: firstly, that medicines may be optimised by considering 370 
patient choice in the clinical decision to prescribe a particular method or route of 371 
administration. Prescribers should be alert to the alternative options for subcutaneously 372 
administered medicines, and consider the range of factors that are likely to influence 373 
patients’ adherence with treatment. Secondly, pharmaceutical companies often cite patient 374 
preference as a justification for price premiums. Their value dossiers and health technology 375 
assessment reports typically suggest that patients favour some methods or routes of drug 376 
administration more than others, and that this can lead to improvement in health outcomes. 377 
Our review illustrates that evidence underpinning such claims is weak. 378 
 379 
Conclusions 380 
 381 
The review identified a number of studies showing the importance of the methods and routes 382 
of drug delivery on patient choice. To improve the evidence base, however, we propose that 383 
future studies of patients’ perspectives of injectable devices should consider using validated 384 
preference measures, combined with a choice-based experiment for stated preference 385 
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elicitation, and reliable adherence measurement [5] for revealed preferences. Studies need 386 
to be unbiased and appropriately powered for demonstrating statistical significance. 387 
 388 
  389 
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